Theodore J. Cohen, Ph.D., a research scientist, has been an investor for more than 50 years. Since 1980, he has focused his attention on investment research and investigative analyses of companies developing therapeutic drugs in the biotech sector. Dr. Cohen is a frequent contributor of Guest Opinions (op-ed pieces) to the Bucks County (PA) Courier Times (circulation: 80,000), where, since 2007, he has addressed such varied subjects as the conflicts of interest (COIs) associated with two members of the Provenge advisory committee (AC); the U.S. Senate’s Durbin Amendment, to tighten COI reviews of FDA AC members; and naked short selling. Cohen is the author of the award-winning novels Death by Wall Street: Rampage of the Bulls (AuthorHouse, 2010) and House of Cards: Dead Men Tell No Tales (Outskirts Press, 2011), which were inspired by real events. The books are available from Amazon.com, B&N, and 26,000 online bookstores worldwide. For details, see http://www.theodore-cohen-novels.com.
I am currently a Junior at the George Washington University and have been investing since the sixth grade with my own money. I am very interested in the pharmaceutical sectors, but will buy just about any stock if I feel that the company is undervalued. I hope to provide some helpful insight, and to in turn learn a lot from the rest of the investment community.
Over 30 years of investing in individual stocks. Extensive business experience with small to mid-size companies, including as CEO. Many hundreds of blog posts on financial and economic matters since 2008. Focus on value with catalysts for upside price action. Background as a physician and pharmaceutical inventor and entrepreneur, however focus now is global and involves almost all economic categories.
A veteran of the pharma industry. Specializing in the analysis of small pharma companies with a focus on the pipeline and opportunities for licensing or major deals with large pharma. Financial analysis including burn rate, venture capital funding, and cash flow.
The founding members of Chimera Research Group have over 50 years of combined experience in the biotech and pharmaceutical sector. Their experience includes work at Investment Banks, Hedge Funds, Pharmaceutical Companies, top-tier Universities, and the U.S. Food and Drug Administration (FDA). Their published work includes freelance and editorial contributions both print and on-line, clinical and medical research, books and tutorials, as well as contributions to on-line social media. Through these and other activities they were able to collaborate and connect amongst themselves to establish this cadre of like-minded biotech/pharma trading and investing aficionados.
The Team includes:
Chief Scientific Analyst - Jason Chew
Chief Research Analyst - Patrick Crutcher
Chief Medical Analyst - Dr. Tro Kalayjian
CEO & Trading Analyst - Tony Pelz
Research Analyst - Dr. Andrew Goodwin
Research Analyst - Dr. Juan Pedro Rodríguez Serrate
Technical Analyst - Joe Gantoss
Research Analyst - Dr. Steven Murphy
Many year investor now into options still learning a great deal and trying to control my emotions. Like tech and biotech as well as some commodities. Like dividend players a lot ESP MLPs. And some Reits. Learning more and more about options for added leverage. Am a physician Therefore have a better understanding of biotech products and binary trades
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Mid Market M&A consultant specializing in technology and energy industries. Individual Investor for over 25 years. Growth oriented investments primarily in market leaders and technology leaders. Investment philosophy is long term buy and hold with average holding time of several years.
I have a keen sense of cutting through management and Investment banker commentary and seeing true value of companies. A lot of my views tend to be controversial for that reason but at the same time remarkably accurate.
To get a feel for my writing, readers can puruse a few of my recent against the grain calls:- with extremely high success rates.
Tech Analyst and opportunistic investor focused primarily on micro caps and up and coming technology companies. I am currently in discussions with a partner to develop and launch a investment premium newsletter website. If you are interested in learning more about my premium newsletter or would like to be added to my mailing list you can inbox me.
You can follow my personal trades and invest your own money with me via Instavest www.instavest.com My focus is on ground breaking technology and the companies that will deliver them in the future. I have managed a family portfolio since 2008 that has been focused on growth and income generation. You can follow me on twitter @MattMargolis24
Steven currently focuses his analyses primarily on the valuation of smaller biotechs (100MM to 1 BB market cap) and utilizes all sources of information, including conversations with management, peer-reviewed publications, SEC filings, and all available primary and secondary research.
Steven is currently a consultant for a New York based life science focused consultancy, and brings a strong scientific and financial background to his current position.
Previously, Steven earned a Ph.D. from the Scripps Research Institute and an M.A. from Columbia University, with extensive work in the field of synthetic and medicinal chemistry, publishing several papers in prestigious peer-reviewed journals. He is also pursuing the CFA designation, and has completed exam level 2.
Please email me with any questions, comments, and investment ideas. (stevenb29 at gmail.com)
Investing for over 30 years, spent some time as a broker. Very interested in markets and geopolitical effects.
Nature and animal lover, interested in health and nutrition, history buff, investments skewed to the biotech sector.
I have a PhD in synthetic organic chemistry. I have conducted research in the area of organometallic chemistry, the chemistry of in vivo imaging agents and other topics. My team was responsible for the chemical development of an ultrasound imaging agent which is now in clinical trials. My current research interests include targeted ultrasound imaging contrast agents and blood substitutes. Since 1998 I have followed the display industry closely. This includes developments in LCD, OLED, TMOS, Thick film dielectric, FED (field emission display), CNTs, elctrowetting (E-ink) and Mirasol. Corollary to this I have followed surface modified films in a number of contexts including light outcoupling, medical applications and uses as screen protectants.
I am a buyside analyst with a medium-sized asset management firm and have been in the investment business for several decades, the majority of that time on the sell side of the business. For my own account, I am a long-term investor and trade my own account infrequently, as I look for either best-of-breed companies trading at depressed prices due to cyclical but temporary factors or small-to-medium-sized companies with promising "disruptive" technologies that have superior growth potential.
Analyst and Fund Manager with almost 20 years investment experience. Coverage includes a variety of industries, with a focus on technology.
Particularly focused on value stocks, poorly understood or under-followed situations, and contrarian perspectives.
Primarily invest in special situations with value that is poorly understood or not fully appreciated, or where we believe there is a highly asymetric risk/reward profile. Also look for long/short ideas in mid/larger cap names where we believe we have a variant view, and the market is dramatically mispricing value.
Follow me on Twitter @valinsights
I am a young mechanical engineer who has used the past 5 years (aside from my day job) to lay the foundation for my future in investments. From reading books from Benjamin Graham to Peter Lynch or reading countless annual reports, there are a few bedrocks from which I have built and will continue to build upon. First and foremost is safety of capital, I will not invest in or try to learn about speculative financial instruments. Second, I look for companies or assets that have a history of good returns on invested capital and utilize moderate to low levels of debt. I trade infrequently and I am triggered only when my estimate of fair value and the current margin of safety against that value are advantageous. Improving my capital allocation is my key goal moving forward.
When I feel a situation has been misunderstood/mispriced by the market and I see a high probability of success, I will write an article detailing those findings. Unfortunately, my time is limited so articles will be scarce. In addition to this, I am not a financial advisor and all due diligence should be performed by the reader.
I have been investing in both growth and value stocks for over 30 years. I enjoy searching for and discovering little known companies with great potential for capital appreciation as well as larger companies that I feel are undervalued. My main focus when searching for these gems is the tech sector as that is where my passion and experience have been for years. However, I comb all sectors to look for the best investment opportunities.
The Green River Intrinsic Value fund is a relatively concentrated, long/short equity strategy. The fund seeks long-term absolute returns investing in deeply mispriced securities which are identified through a careful process of methodical fundamental research and due diligence.